The significant impact of cardiovascular disease on human morbidity and mortality alongside the proven efficacy of many lipid-modifying therapies drives both the aggressive treatment of dyslipidemia by physicians and the generous reimbursement of therapies among U.S. health plans. Some branded therapies continue to receive generous reimbursement from health plans despite the availability of in-class generics because they possess highly valued qualities or capabilities such as improved risk reduction, higher potency or better tolerability. A number of upcoming events may reshape the reimbursement landscape for dyslipidemia including generic entry of Pfizer's blockbuster statin, Lipitor (atorvastatin), in 2012 and the likely emergence of two first-in class therapies, Genzyme/Isis' mipomersen and Roche's dalcetrapib. Using tiering and restrictions data from Fingertip Formulary, as well as insight from 50 pharmacy directors, this report determines the key trends in reimbursement of therapies for dyslipidemia, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition.

Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details